The incidence of pregnancy induced hypertension (PIH), one of the most frequent causes of maternal and neonatal morbidity, has increased significantly in the U.S. in last two decades. However, reasons for this rise are not well explored. The interrelationship between interpregnancy interval (IPI), prepregnancy body mass index (BMI), and PIH might play a role in this rise. This study aims to investigate the additive effect of IPI and prepregnancy BMI on PIH.
The 2018 Vital Statistics Natality Data was analyzed (N=1,046,350) for this cross-sectional study. https://www.selleckchem.com/products/sbfi-26.html A combined variable was created using IPI and prepregnancy BMI. Adjusted odds ratios and 95% confidence intervals were generated for IPI, prepregnancy BMI, and PIH using multiple logistic regression models.
PIH was defined using the birth certificate variable 'Gestational hypertension- (PIH, preeclampsia)' in the dataset.
IPI and prepregnancy BMI were statistically significantly associated with PIH, both independently and in combination, after adjusting for potential confounders. The largest effect size was observed among women with long IPI and obesity (Adjusted OR=4.01, 95% CI=3.84, 4.25). Further, short IPI in combination with underweight BMI was found to be inversely associated with PIH (AOR=0.64, 95% CI=0.53, 0.78).
When combined, IPI and BMI are crucial risk factors for PIH. The highest risk of PIH is in women with long IPI in combination with high BMI categories. Healthcare professionals should be cognizant of the additional increased risk of PIH for the overweight and obese women with long IPI.
When combined, IPI and BMI are crucial risk factors for PIH. The highest risk of PIH is in women with long IPI in combination with high BMI categories. Healthcare professionals should be cognizant of the additional increased risk of PIH for the overweight and obese women with long IPI.Low levels of estradiol in women have been associated with impaired fear extinction recall, with suggestions this may promote the return of fear and heighten the female vulnerability for anxiety disorders. A particularly important measure for the return of fear is reinstatement, but no human studies to date have examined the impact of estradiol on fear reinstatement. Forty-two healthy females completed a differential fear conditioning, extinction and reinstatement task with skin conductance response (SCR) amplitude indexing level of conditioned fear. Saliva samples were taken to measure estradiol and progesterone. To examine fear reinstatement, SCR amplitude was compared between the last trial of the late extinction phase to the first re-extinction trial following the unsignaled presentation of two aversive electric shocks. No significant effects of estradiol were found for acquisition of fear conditioning or fear extinction learning. Lower estradiol predicted a significantly larger generalized SCR amplitude at re-extinction (post-reinstatement) in women. This provides novel evidence suggesting a protective role of estradiol in potentially reducing the relapse of fear following re-exposure to aversive stimuli, although further research is necessary in clinical populations to clarify this effect.Many patients who receive cognitive behavior therapy (CBT) for mood and anxiety disorders fail to respond or drop out of treatment. We tested the hypotheses that therapist use of each of three decision support tools, a written case formulation, a list of treatment goals, and a plot of symptom scores, was associated with improved outcome and reduced dropout in naturalistic CBT provided to 845 patients in a private practice setting. We conducted regression analyses to test the hypotheses that the presence of each tool in the clinical record was associated with lower end-of-treatment scores on the Beck Depression Inventory (BDI) and the Burns Anxiety Inventory (BurnsAI), and lower rates of premature and uncollaborative dropout. We found that the presence of a written case formulation in the clinical record was associated with lower rates of both types of dropout. A list of treatment goals was associated with lower end-of-treatment scores on the BDI and the BurnsAI, and a lower rate of uncollaborative but a higher rate of premature dropout. A plot of symptom scores was associated with lower end-of-treatment scores on the BDI, and lower rates of both types of dropout. Results suggest that therapist use of a written case formulation, list of treatment goals, and a plot of symptom scores can contribute to improved outcome and reduced dropout in CBT.Phthalates, which are commonly used in flexible plastics and consumer products, have been reported to be toxic to reproductive and developmental function in mammals. Past studies have focused on the toxic effects on male reproduction, with only a few studies conducted on the risks that cumulative exposure to phthalates have on the female reproductive system. We recruited 260 patients with recurrent pregnancy loss (RPL) of unknown etiology and 203 controls from the clinics of Obstetrics and Gynecology at a medical center in southern Taiwan from 2013 to 2020. The daily intake of phthalates was estimated from urine samples using the back-calculation method, after which the cumulative risk was determined using multiple hazard indices, including a dose-addition model, a receptor effect model, and a hazard index approach. The patients with RPL had a significantly higher cumulative exposure to phthalates (p less then 0.05) than did the controls with a hazard index above one. After adjusted logistic regression analysis, we found that the risk of RPL was strongly related to the higher quartiles of DEHP, the DEHPTEQ for the antiandrogenic effect and adverse effects of the female reproductive system and the ERα binding effect (p less then 0.05). Our work suggests that more attentions should be paid to the adverse effects induced by phthalates on female reproduction, especially the effects caused by the cumulative exposure to phthalates in women of reproductive age.Although it is generally accepted that negative symptoms of schizophrenia are associated with larger lateral ventricles, this general assumption could not be validated in patients with primary negative symptoms. To elucidate this issue, we conducted a five-year longitudinal study, including deficit (n = 13) and non-deficit (n = 26) schizophrenia patients with healthy controls (n = 18). Analysis with linear mixed effects modeling showed that both the left and the right lateral ventricles of the deficit patients enlarged more than the non-deficit patients. Our results suggest that structural alterations in deficit patients might follow a different trajectory than those in non-deficit patients.